

Serum Institute, Cipla launch Hepatitis B vaccine in India

<https://www.biovoicenews.com/serum-institute-cipla-launch-hepatitis-b-vaccine-india/>

By : BioVoice News Desk - March 3, 2017



Pune: Under a co-exclusive agreement with Serum Institute of India (SII), global pharmaceutical company Cipla has launched adult Hepatitis B vaccine in India. Cipla will market the vaccine for adults while SII will market it for adults and children.

Commenting on the launch, Umang Vohra, MD and Global CEO Cipla said, “This agreement will enable Cipla to provide affordable vaccines for a chronic disease like Hepatitis B. Cipla’s strong marketing network and reach will ensure maximum accessibility of the vaccines in India. This vaccine is able to protect 95 percent of recipients from developing chronic Hepatitis B.”

The vaccine is given in three doses that include one after the first month of the first dose and the second after 6 months post the first dose. The vaccine can protect the recipient from this infection for decades. In addition, it is expected to bring down the number of cases of liver cirrhosis and liver cancer.